Related Announcements

PAS-19-317 - Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)

Issued by

National Institute on Aging (NIA)

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The purpose of this notice is to correct the Award Project Period information for Funding Opportunity Announcement (FOA) PAS-19-317, "Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional).” Specifically, according to statutory guidelines, award periods normally may not exceed 2 years for Phase I and 3 years for Phase II. As such, NIA has changed the award period for Phase I from 1 year to 2 years and the award period for Phase II from 2 years to 3 years.

The following section of PAS-19-317 has been modifed:

Currently Reads:

Part 2. Full Text of Announcement

Section II. Award Information, Award Project Period

According to statutory guidelines, award periods normally may not exceed 1 year for Phase I and 2 years for Phase II.

Modified to Read (changes shown in bold italics):

Part 2. Full Text of Announcement

Section II. Award Information, Award Project Period

According to statutory guidelines, award periods normally may not exceed 2 years for Phase I and 3 years for Phase II.

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Zane Martin, Ph.D.
National Institute on Aging (NIA)
Division of Neuroscience (DN)
Telephone: 301-827-7130
Email: [email protected]

Michael-David ARR Kerns, M.M., M.S., Ph.D.
National Institute on Aging (NIA)
NIA SBIR-STTR Program Coordinator
Telephone: 301-402-7713
Email: [email protected])

Natalie Trzcinski, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1779
E-mail: [email protected]